12 Best Healthcare Stocks to Buy According to Analysts

3) Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 14

Average Upside Potential: 83.3%

Genmab A/S (NASDAQ:GMAB) develops antibody therapeutics for the treatment of cancer and other diseases. H.C. Wainwright analyst Ram Selvaraju reiterated a “Buy” rating on the company’s shares, setting a price target of $50.00. The rating is backed by a combination of factors including the consistent performance of the company’s DARZALEX, which achieved significant worldwide sales in line with anticipations. Notably, Genmab A/S (NASDAQ:GMAB) reported that net sales of DARZALEX in 2024 came in at US$11,670 million.

As per the analyst, the strong sales figures, mainly in the US market, underscore the franchise’s strong growth trajectory and reinforce confidence in the market positioning. The net trade sales came in at US$6,588 million in the US and US$5,082 million in the rest of the world. Genmab A/S (NASDAQ:GMAB)’s extensive pipeline, featuring candidates such as EPKINLY, and expertise in antibody design are expected to act as near- and medium-term clinical catalysts.

Genmab A/S (NASDAQ:GMAB) continues to operate in a highly competitive oncology market, where innovation and efficacy act as key differentiators. Its strength revolves around the proprietary antibody technology, which continues to yield multiple approved treatments. The company has updated the lower end of its revenue range of 2024 financial guidance due to the higher total royalty revenues from DARZALEX. Notably, it now expects revenue to be in the range of DKK21,100 million – DKK21,700 million, up from DKK20,500 million – DKK21,700 million.